Jatamansi

Otros Nombres

Achte NardeBaalchadBalcharBalcharaBalchharBalchirBalucharBhootjataBhuikohlaBhutajataBhutakeshiBhutijataBhutijattBhutijattaBhytajataBillilotanButijattChakravartiniChharguddiChi ye gan songFedia grandiflora Wall. ex DC.Fedia jatamansi Wall. ex DC.Gan SongGanagila masteGandhamansiGauriHaswaHimalayan spikenardHinsraIndian nardIndian spikenardIndian valerianIndisch aarborstelgrasIndische NardeIndischer BaldrianJananiJapoyJataJatalaJatalasiJatamamsiJatamanchiJatamangshiJatamangsiJatamanjiJatamashiJatamasiJatavaliJatiJatilaJetamanshiKalichadKalichhadKantipradaKeshiKhasambhavaKiratiniKrishnajataKuklipotLaghumansiLeirongLimashaMamsiManchiMansiMansiniMasiMataMishikaMisiMrigabhakshaMusk rootMuskrootNaladaNalandaNardNard de l'HimalayaNard IndianNarde IndikeNardhingaruNardinNardostachys chinensis BatalinNardostachys gracilis Kitam.Nardostachys grandiflora DC.Nardostachys jatamansiNardostachys jatamansi (D.Don) DC.Nardostahyos Radix et RhizomaNardus rootNaswaNirlambaPalamkashaParvatavasiniPatrinia jatamansi D.DonPeshiPeshiniPishachiPishitaPutenaSambul lateebSambul-u-l hindSevaliSha-dkarShvetakeshiSpikenardSukshmajatamansiSukshmapatriSumbul al-wardSumbul-ut-teebSunbul uttibTagaraTapasviniTapaswaniTrue spikenardValeriana jatamansi JonesValeriana jatamansi Wall.Valeriana wallichii DC.VilomasaXiang SongZatamashi

Sinopsis

Jatamansi (Nardostachys jatamansi DC.): A Comprehensive Reference

1. Identity, Taxonomy, and Botanical Description

Jatamansi is the widely used common name for the rhizome-bearing medicinal plant whose accepted scientific name is Nardostachys jatamansi (D.Don) DC. Its scientific name is Nardostachys jatamansi DC., and it carries a range of common names including Balchar, Indian spikenard, Jatamansi, Muskroot, Nardostachyos Radix et Rhizoma, Sambul lateeb, Spikenard, and Sumbul-ut-teeb. A taxonomic synonym is Nardostachys chinensis Batalin.

A member of the family Valerianaceae, Nardostachys jatamansi is the smallest, most primitive, perennial, dwarf, hairy, rhizomatous, herbaceous species in its genus. The genus contains only one species, Nardostachys jatamansi. Its formal taxonomic placement situates it in Kingdom Plantae, Division Magnoliophyta, Class Magnoliopsida, Order Dipsacales, Family Valerianaceae, Genus Nardostachys, Species jatamansi; the principal medicinal part used is the rhizome and rhizome oil.

The plant is approximately 10 to 60 cm in height with stout, long woody root stocks. The rhizomes are 2.5 to 7.5 cm in length, elongated and cylindrical in shape, and dark grey in color with reddish-brown tufted fibers. The radical leaves are elongated and spathulate; some cauline leaves are sessile, oblong, or subovate. The pale pink or blue flowers appear in dense cymes.

Geographic Distribution

The species is found throughout the Himalayas, from Pakistan to India (Jammu and Kashmir, Himachal Pradesh, Uttarakhand, Sikkim), Nepal, Tibet, and China. The Himalayan alpine region's slopes at elevations of 2,200–5,000 m are where the herbs are distributed. In Britain, the Netherlands, Belgium, France, Germany, Eastern Europe, and Japan, it is sourced from both cultivated and wild plants.

Conservation Status

N. jatamansi is listed as critically endangered in the IUCN Red List of Threatened Species and is highly susceptible to overharvesting due to its high commercial value. Nardostachys jatamansi is a critically endangered medicinal plant that is a miniature, perennial herbaceous plant with hairy rhizomes found in the alpine and sub-alpine regions of the Himalayan range.

Medicinal Parts and Common Preparations

Dried rhizomes and roots are the main medicinal parts. The basal leaves are also used in herbal and traditional medicine. The rhizomes or underground stems are crushed and distilled to yield a spikenard essential oil that is intensely aromatic and of thick consistency. This oil is used as an essential oil owing to its deodorant, sedative, antimicrobial, and anti-inflammatory actions.

Several classical dosage forms including hot or cold infusion, decoction, distillate, and powders have been described for jatamansi. In modern supplement markets the plant is encountered as powdered rhizome (churna), encapsulated extracts, medicated oils (taila), and as part of polyherbal Ayurvedic formulations. The roots and rhizomes, as mentioned in Ayurveda, have been used in various herbal formulations including dietary supplements.

2. Traditional and Historical Use

Ancient Civilizations and Pre-Classical Period

Nardostachys jatamansi from India was known to the Mesopotamians, one of the earliest civilizations of the world, and its name was found in their cuneiform script. It was exported to Assyria, to Arabian countries, and to Egypt, where it was known as Sumbul-e-Hind, and to Greece under the name Nardus. The plant is also mentioned in the Bible as Spikenard; in Germany, it was known as Nardus indica. It was reputed as a costly incense herb and perfume, and used as a nerve tonic in hysteria, epileptic fits, and palpitations of the heart in Middle Eastern countries since time immemorial.

Ayurvedic Tradition (India)

This plant has long been recognized for its medical properties in Ayurveda in India, Unani medicine in the history of Greek and Arab cultures, and in ancient Egyptian and Roman cultures. Its use in Ayurveda dates back to the Charaka Samhita and Sushruta Samhita (1st–2nd century CE), where it is classified as a Medhya Rasayana (intellect rejuvenator) and Sangyasthapaka (consciousness restorer).

The rhizomes of this hairy, perennial, dwarf, and herbaceous plant are used for therapeutic effect in the Ayurvedic and Unani systems of medicine. In the Ayurvedic medical system, the rhizomes of the plant are used as a bitter tonic, stimulant, antispasmodic, epileptic treatment, and for hysteria. Jatamansi's Ayurvedic actions include a range of Sanskrit therapeutic categories: its effects extend to Hrid-balya (supporting heart health) and Raktabharaniyamaka (aiding in maintaining proper blood circulation). Furthermore, it is known for its Vajikara effects, enhancing fertility and vitality. It helps in managing Pitta dosha (Pittasaraka) and supports female reproductive health through Artavajanana (promoting menstrual health). The herb has a role in inducing sweat (Swedajanana) and addressing skin conditions (Kushthaghna).

The roots and rhizomes of Nardostachys jatamansi have been used to treat hysteria, syncope, epilepsy, and mental weakness. This important traditional drug is also used to treat epilepsy, hysteria, syncope, convulsions, and mental weakness; the decoction of the drug is used in neurological disorders, insomnia, and disorders of the cardiovascular system.

Unani and Greco-Arab Traditions

N. jatamansi has been used in the traditional Ayurvedic (Indian) and Unani (ancient Greco-Arab) medical systems. In the Unani system, the plant's roots were employed for the treatment of various ailments including liver and inflammatory conditions. The roots of Nardostachys jatamansi are utilized in traditional Unani medicine for the treatment of various ailments, including hepatitis and inflammation.

Traditional Chinese Medicine

Nardostachys jatamansi DC. is a valued herb in traditional Chinese medicine, historically used to regulate qi flow, alleviate pain, and enhance digestive function. It has been extensively employed in traditional medical systems including Ayurveda, Tibetan medicine, and Traditional Chinese Medicine (TCM) for the management of neurological disorders, digestive complaints, and cardiovascular conditions. In Chinese medicine the plant is known as Gansong and has been historically employed in the management of various neuropsychiatric disorders.

3. Phytochemistry: Key Constituents and Active Compounds

Sesquiterpene is the major component of N. jatamansi plant and includes jatamansone and nardostachone as principal sesquiterpene compounds. The sesquiterpenes (jatamansic acid, jatamansone), lignans, and neolignans are reported to be present in the roots of this plant. Rhizomes are reported to contain a terpenoid ester, nardostachysin I.

A comprehensive list of identified compounds includes, but is not limited to: alpha-patchoulenese, angelicin, beta-eudesmol, beta-patchoulenese, beta-sitosterol, calarene, calarenol, elemol, jatamansin, jatamansinol, jatamansone, n-hexacosane, n-hexacosanol, n-hexacosanyl arachidate, n-hexacosanyl isovalerate, nardol, nardostachone, norsechelanone, oroselol, patchouli alcohol, seychelane, seychellene, valeranal, and valeranone. Additional identified constituents include volatile essential oil, resin, sugars, starch, bitter extractive matter, gum, jatamansone, jatamansic acid, jatamansone semicarbazone, lupeol, malliene, calarene, the terpenic coumarin jatamansin, oroselol, the dietheniod bicyclic ketone nardostachone, and the sesquiterpene ketone jatamansone.

The essential oil has a complex chemical profile. The extraction yield of the essential oil (NJEO) by hydrodistillation is approximately 4.28%. GC–MS analysis identified 30 compounds (accounting for 99.61% of total oil), with terpenes (68.83%) and aromatic compounds (15.01%) as the major fractions.

Nardosinone, a sesquiterpenoid compound, has been identified as one of the principal bioactive constituents of N. jatamansi. Various sesquiterpenes (such as jatamansic acid and jatamansone), lignans, alkaloids, coumarins, and neolignans have been reported to be present in the roots of the plant.

Major Bioactive Compounds and Their Roles

Jatamansone (desoxo-narchinol): The principal sesquiterpene ketone. Jatamansone has been linked to anti-hypertensive, anti-arrhythmic, anti-asthmatic, nematicidal, and antibacterial effects.
Nardostachone: Jatamansone, nardostachone, and actinidine are the major secondary metabolites present in the plant.
Jatamansinol: Jatamansinol from Nardostachys jatamansi has been described as a multitargeted neuroprotective drug against human Tau-induced neurotoxicity in Alzheimer's disease models. In Tau protein-expressed cells, jatamansinol reduces the production of reactive oxygen species and boosts the activities of antioxidant enzymes.
Valeranone and jatamansone (as sedative agents): Valeranone and jatamansone in the essential oil (NJEO) exert sedative effects by modulating GABA receptors.
Patchouli alcohol: Patchouli alcohol exhibits anti-inflammatory, antibacterial, and antioxidant activities.
Nardosinone: Nardosinone has been studied for its effects on neuroinflammatory mediator release, glucose metabolic reprogramming, and T cell migration using both in vitro and in vivo experimental models.
Aristolone: Aristolone in Nardostachys jatamansi DC. induces mesenteric vasodilation and ameliorates hypertension via activation of the KATP channel and PDK1-Akt-eNOS pathway.
Jatamansinone and related coumarins: Molecular docking studies revealed that jatamansinone (−9.729 kcal/mol), eselin (−9.138 kcal/mol), and jatamansinol (−8.979 kcal/mol) exhibited strong binding affinities with MAO-B, comparable to the reference inhibitor safinamide (−10.66 kcal/mol). These phytochemicals effectively occupied the active site, interacting with key residues such as Tyr326.

4. Mechanisms of Action

Central Nervous System: GABAergic and Monoaminergic Pathways

Ethanolic extract (100, 200, and 400 mg/kg, p.o.) of N. jatamansi administered for 14 successive days to mice produced significant antidepressant-like effect in both tail suspension and forced swim tests, with efficacy found to be comparable to imipramine (15 mg/kg, p.o.) and sertraline (20 mg/kg, p.o.). The extract at 200 mg/kg did not produce any motor effects. It decreased the whole brain MAO-A and MAO-B activities as compared to control, thus increasing the levels of monoamines. The antidepressant effect was significantly reversed by pretreatment with baclofen (a GABA-B agonist), suggesting the antidepressant-like effect may also be due to interaction with GABA-B receptors, resulting in decreased levels of GABA.

The antidepressant-like effect of the petroleum ether extract was significantly reversed by pretreatment with prazosin (an α1-adrenoceptor antagonist), sulpiride (a selective dopamine D2-receptor antagonist), p-CPA (a serotonin synthesis inhibitor), and baclofen (a GABA-B agonist) in the tail suspension test. The petroleum ether extract also reduced mouse whole brain monoamine oxidase (MAO-A and MAO-B) activities, resulting in increased levels of brain monoamines.

Nardostachys jatamansi has anxiolytic property and increases brain monoamines. Prediction of Activity Spectra for Substances (PASS) analysis predicted a wide range of neuroprotective properties of its phytochemicals, including antioxidant, anti-inflammatory, neurotransmitter-modulating, and motor-stabilizing activities. Their predicted ability to influence the serotonin and GABA pathways further highlights their potential as promising natural agents for the treatment or prevention of Parkinson's disease and related neurodegenerative disorders.

Antioxidant Mechanisms

Nardostachys jatamansi, an indigenous medicinal plant, induces in the organism a state of resistance against stress and helps to promote physical and mental health, augment resistance of the body against disease, and has shown potent antioxidant activity. Treatment of mice with N. jatamansi extract before irradiation caused a significant depletion in lipid peroxidation, followed by significant elevation in reduced glutathione, total antioxidants, glutathione peroxidase, and catalase activity. It also showed a reduction in micronucleus formation in the bone marrow cells. The radioprotective activity of N. jatamansi extract may be attributable to free radical scavenging and increased antioxidant levels.

Since free radicals have been implicated in the pathogenesis of a considerable range of neurological disorders including seizures and epilepsy, analysis of antioxidant activities and phenolic profiles was carried out; N. jatamansi expressed better antioxidant activity with both DPPH and TAC methods.

The essential oil (NJEO) exhibited significant radical scavenging activity, with superoxide scavenging capacity superior to ascorbic acid.

Anti-neuroinflammatory Mechanisms

Both the ethyl acetate extract (NJ-1A) and nardosinone could significantly suppress LPS-induced production of M1 pro-inflammatory factors or markers in microglia and could inhibit the glycolytic process. The effects of NJ-1A and nardosinone on neuroinflammatory mediator release, glucose metabolic reprogramming, and T cell migration were investigated using both in vitro and in vivo experimental models.

Cardiovascular Mechanisms

The vasodilator, bronchodilator, spasmolytic, and platelet aggregation inhibition activities of the plant have also been reported. The hypotensive activity has been linked to specific constituents; aristolone in N. jatamansi DC. induces mesenteric vasodilation and ameliorates hypertension via activation of the KATP channel and PDK1-Akt-eNOS pathway.

5. Scientific Evidence by Area of Use

5.1 Central Nervous System Depressant / Sedative Activity

Animal and in vitro evidence: The plant shows marked tranquilizing activity, as well as hypotensive, hypolipidemic, hepatoprotective, neuroprotective, anti-ischemic, antiarrhythmic, and anticonvulsant activities in experimental models. The essential oil obtained from the roots shows various pharmacological activities including antimicrobial, antifungal, hypotensive, anti-arrhythmic, and anticonvulsant activity.

Evidence strength: The scientific literature contains primarily phytochemical and animal studies of N. jatamansi's activity on the nervous system and the cardiovascular system. Clinical trial data are lacking to recommend use for any indication.

5.2 Insomnia (Anidra)

Clinical evidence: N. jatamansi powdered rhizome at a dose of 4 g with milk three times a day after food for 1 month was used in a small study evaluating effects on primary insomnia. A comparative clinical study referenced in the PubMed literature by Toolika et al. (2015), published in Ayu, compared the effect of Tagara (Valeriana wallichii DC.) and Jatamansi (Nardostachys jatamansi DC.) in the management of Anidra (primary insomnia). In a further multi-herb combination study, 24 patients with insomnia were given a hydroalcoholic extract derived from roots of Tagara, the rhizome of Jatamansi [Nardostachys jatamansi (D.Don) DC.], and the rhizome of Vacha (Acorus calamus L.) in capsule form at a ratio of 2:1:1, respectively, for 15 days.

Clinical trials of Jatamansi Oil (JO) as a head massage conducted by clinicians and therapists have shown encouraging results in de-stressing/stress management of cancer patients through head anointing treatment. Previous studies on Shirodhara oil prepared from Centella asiatica (Brahmi), Nardostachys jatamansi (Jatamansi), and Withania somnifera (Ashwagandha) have shown significant relief in mood scores and stress levels (P < 0.001) along with decreased breathing rate, diastolic blood pressure, and heart rate. The relaxed alert state post-Shirodhara treatment was denoted by an elevation in the alpha rhythm of the electroencephalogram.

Evidence strength: Preliminary. The existing human trials are small, often unblinded or of short duration, and many involve polyherbal formulations rather than jatamansi as a single ingredient, making it impossible to attribute effects solely to N. jatamansi.

5.3 Anxiety and Depression

Animal evidence: Ethanolic extract (100, 200, and 400 mg/kg, p.o.) of N. jatamansi administered for 14 successive days to Swiss young albino mice produced significant antidepressant-like effects in both tail suspension and forced swim tests, with efficacy comparable to imipramine (15 mg/kg, p.o.) and sertraline (20 mg/kg, p.o.). Ethanolic extract (200 mg/kg, p.o.) did not show any significant change on locomotor activity. The extract decreased the whole brain MAO-A and MAO-B activities, thus increasing levels of monoamines. The antidepressant effect was also significantly reversed by pretreatment with baclofen (a GABA-B agonist).

Human/clinical evidence: A randomized controlled double-blind clinical trial comparing two groups with 38 subjects each investigated the efficacy of Jatamansi in Generalized Anxiety Disorder (GAD) versus imipramine. Various preclinical and clinical studies had previously shown anxiolytic activity of Jatamansi, prompting a study to assess its effects in Generalized Anxiety Disorder. A further PubMed-indexed study (published 2025) examined the efficacy of Nardostachys jatamansi DC. as an adjuvant to escitalopram in the treatment of major depressive disorder — a randomized double-blind placebo-controlled study.

Evidence strength: Weak to preliminary for human use. Preclinical animal mechanistic data are informative but cannot be directly extrapolated to humans. The clinical trials that exist are small and have methodological limitations; no regulatory body has accepted these data as sufficient to substantiate a health claim.

5.4 Hypertension

Clinical evidence: The aim of the study was to examine the efficacy of Nardostachys jatamansi in reducing blood pressure in hypertensive patients. This single-blind randomized, placebo-controlled study was conducted with 40 patients aged between 35–70 years. Participants were randomly allocated to receive either a total of 3 g of N. jatamansi (1 capsule three times a day) or placebo for 4 weeks. Patients using ≤2 antihypertensive drugs with stage 1 hypertension were included. Systolic and diastolic blood pressure was recorded at baseline and at every week for four weeks. MINICHAL score (for quality of life) was recorded at baseline and at the end of the trial.

After the four weeks of treatment, there was a statistically significant reduction in average systolic blood pressure from 144.20 ± 11.35 mmHg (CI, 138.89–149.51) to 134.30 ± 10.08 mmHg (CI, 129.58–139.02), p < 0.001), and diastolic blood pressure was also significantly reduced. These findings suggest that Nardostachys jatamansi is effective in reducing both systolic and diastolic blood pressure in hypertensive patients and also improved the quality of life of these patients.

Evidence strength: Limited. This is a single small trial (40 patients, 4 weeks, single-blind) in patients already on antihypertensive medication. The study design precludes strong causal inference. Replication in larger, longer, independently conducted trials is needed.

5.5 Neuroprotection: Alzheimer's Disease and Cognitive Function

Preclinical evidence: Nardostachys jatamansi has been studied for anti-Alzheimer activity. Jatamansinol from Nardostachys jatamansi has been described as a multitargeted neuroprotective drug against human Tau-induced neurotoxicity in the Alzheimer's disease Drosophila model. In Tau protein-expressing cells, jatamansinol reduces the production of reactive oxygen species and boosts the activities of antioxidant enzymes.

Despite the broad-spectrum utility of Nardostachys jatamansi, little is known about the molecular processes that underlie its anti-Alzheimer action. To investigate the molecular targets and therapeutic potential of N. jatamansi for Alzheimer's disease (AD), researchers have used GC-MS, ADMET analysis, network pharmacology, differential gene expression analysis, molecular docking, and molecular dynamics simulations.

It is also reported to improve learning and memory in mice.

Evidence strength: Purely preclinical (animal, cell-based, in silico). No adequately powered human clinical trials for Alzheimer's disease or cognitive enhancement have been published.

5.6 Anti-Parkinsonian Activity

Preclinical evidence: This study investigated the effects of ethyl acetate extract (NJ-1A) from N. jatamansi and its active constituent nardosinone on neuroinflammatory mediator release, glucose metabolic reprogramming, and T cell migration using in vitro and in vivo models. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid (MPTP/p)-induced male C57BL/6N mouse chronic model of Parkinson's disease was applied. Both NJ-1A and nardosinone could significantly suppress LPS-induced production of M1 pro-inflammatory factors or markers in microglia and could inhibit the glycolytic process.

Computational evidence: Molecular docking studies revealed that jatamansinone (−9.729 kcal/mol), eselin (−9.138 kcal/mol), and jatamansinol (−8.979 kcal/mol) exhibited strong binding affinities with MAO-B, comparable to the reference inhibitor safinamide (−10.66 kcal/mol). These phytochemicals effectively occupied the active site, interacting with key residues such as Tyr326, suggesting a mechanism of inhibition similar to that of safinamide.

Evidence strength: Preclinical and computational only. No human trials have been conducted.

5.7 Hepatoprotective Activity

Animal evidence: A 50% ethanolic extract of the rhizomes of N. jatamansi was shown to possess hepatoprotective activity. Pretreatment of rats with the extract (800 mg/kg body weight, orally) for three consecutive days significantly ameliorated liver damage in rats exposed to the hepatotoxic compound thioacetamide. Elevated levels of serum transaminases (aminotransferases) and alkaline phosphatase observed in the thioacetamide-treated group were significantly lowered in N. jatamansi pretreated rats. Pretreatment also resulted in an increase in survival in rats intoxicated with the LD90 dose of the hepatotoxic drug.

Evidence strength: Animal-model evidence only. No human hepatoprotection trials have been reported.

5.8 Anticonvulsant Activity

N. jatamansi is reported to possess anticonvulsant activity. It has been traditionally used in the Ayurvedic system of medicine as a neuroprotective agent for the treatment of hysteria, epilepsy, insomnia, and convulsions. Experimental pharmacological reports corroborate the anticonvulsant potential, consistent with its GABAergic modulation mechanism, but human clinical trial data specifically for epilepsy are absent from the indexed literature.

Evidence strength: Preclinical (animal) only.

5.9 Antiarrhythmic Activity

N. jatamansi is reported to possess antiarrhythmic activity. It has also shown marked tranquilizing activity, as well as hypotensive, hypolipidemic, antiischemic, antiarrhythmic, hepatoprotective, anticonvulsant, and neuroprotective activities in animal studies.

Evidence strength: Preclinical only. No controlled human trials have been conducted for arrhythmia.

5.10 Antioxidant and Radioprotective Activity

Nardostachys jatamansi, an indigenous medicinal plant, induces in the organism a state of resistance against stress, helps to promote physical and mental health, augments resistance of the body against disease, and has shown potent antioxidant activity. Treatment of mice with N. jatamansi extract before irradiation caused significant depletion in lipid peroxidation followed by significant elevation in reduced glutathione, total antioxidants, glutathione peroxidase, and catalase activity. It also showed a reduction in micronucleus formation in the bone marrow cells. These results indicate that the radioprotective activity may be due to free radical scavenging and increased antioxidant levels.

Evidence strength: Preclinical (animal, in vitro) only.

6. Body Systems and Health Areas of Association

Based on the assembled pharmacological literature, N. jatamansi has been most consistently associated with the following body systems:

Central Nervous System: It is used in the treatment of insomnia and CNS disorders. Reported activities include sedation, anxiolysis, antidepressant effects, anticonvulsant actions, and neuroprotection.
Cardiovascular System: It also exhibits cardioprotective activity and is used in the treatment of neural diseases. Antihypertensive and antiarrhythmic effects have been reported in animal models and one small human trial.
Hepatic System: Animal studies support hepatoprotective effects via antioxidant mechanisms, as detailed above.
Neurodegenerative Disorders: It has been reported by several researchers as antispasmodic, antiepileptic, hepatoprotective, anticonvulsant, neuroprotective, anti-Alzheimer's, anti-Parkinson's, and antidepressant.
Dermatological: Traditional uses in Ayurveda include treatments for neurological, cardiovascular, and dermatological conditions.
Reproductive/Hormonal: It is known for its Vajikara effects, enhancing fertility and vitality, and supports female reproductive health through Artavajanana (promoting menstrual health).
Digestive System: N. jatamansi has been reportedly used to treat various disorders, including digestive, nervous, respiratory, urinary, circulatory, and reproductive disorders.

7. Dosage Forms and Doses Reported in Studies

The following dosages are reported directly from source documents and should be understood as study-specific, not as therapeutic recommendations:

Hypertension trial (Bhat and Malik, 2020, Complement Ther Med): In a small 4-week study, an N. jatamansi dosage of 3 g/day (i.e., one 1 g capsule three times a day) was used to evaluate potential blood pressure-lowering effects in patients with hypertension.
Primary insomnia study: N. jatamansi powdered rhizome at a dose of 4 g with milk three times a day after food for 1 month was used in a small study evaluating effects on primary insomnia.
Multi-herb insomnia trial: In an open-labeled, randomized clinical trial, 24 patients with insomnia were given a hydroalcoholic extract from roots of Tagara, rhizome of Jatamansi, and rhizome of Vacha in capsule form in the ratio of 2:1:1, respectively, for 15 days.
Animal antidepressant studies: Ethanolic extract at 100, 200, and 400 mg/kg, p.o., administered for 14 successive days produced significant antidepressant-like effect in mice, with efficacy comparable to imipramine (15 mg/kg, p.o.) and sertraline (20 mg/kg, p.o.).
Animal hepatoprotective study: A 50% ethanolic extract of rhizomes at 800 mg/kg body weight orally for three consecutive days significantly ameliorated liver damage in rats exposed to thioacetamide.
Classical Ayurvedic preparations: Several classical dosage forms like hot or cold infusion, decoction, distillate, and powders have been mentioned for jatamansi. In one preparation, Jatamansi Oil (JO) was prepared by evaporating its decoction in sesame oil.

8. Safety Considerations and Notable Interactions

Adverse Effects at High Doses

Jatamansi, when consumed in large doses, causes vomiting and diarrhea with abdominal pain, nausea, colic, and urinary problems. Excess dose of jatamansi leads to vomiting, nausea, diarrhea, abdominal pain, and may also cause urinary problems.

Tolerability in Small Human Trials

In the Bhat and Malik (2020) hypertension trial, no adverse effects were noted in any of the patients during the trial period (this observation applies to a combined formulation trial; clinical monitoring was short-term).

Potential Hepatotoxicity

In silico toxicity profiling of certain compounds found in N. jatamansi warrants attention: hepatotoxicity studies showed that ursolic acid (a compound identified in related species) could cause liver damage on administration; drug-induced liver injury is one of the most frequent causes of acute liver failure. However, it should be noted that animal studies with N. jatamansi extracts have specifically demonstrated hepatoprotective rather than hepatotoxic effects at tested doses, and the ursolic acid concern is derived from in silico (computational) modeling, not confirmed in vivo for this plant specifically.

Cardiac Safety Profile (In Silico)

Toxicity studies indicated that key tested compounds of N. jatamansi were negative for inhibition of hERG I and hERG II. The hERG-coded protein is an important one involved in cardiac repolarization; inhibition of hERG I and hERG II causes blockade of potassium ion channels linked to QT prolongation, which may lead to cardiac arrhythmia. The absence of hERG inhibition for the tested compounds is favorable from a cardiotoxicity perspective, though this remains in silico evidence only.

Monoamine Oxidase Inhibition — Interaction Implications

The extract decreased the whole brain MAO-A and MAO-B activities as compared to control, thus increasing the levels of monoamines. MAO inhibition is a pharmacologically significant property. Concurrent use of an MAO-inhibiting preparation with foods rich in tyramine or with drugs that increase serotonin or noradrenaline (e.g., SSRIs, SNRIs, tricyclic antidepressants, triptans) could theoretically result in unwanted monoaminergic potentiation. This interaction has not been formally characterized in human studies, but the mechanistic basis for it is established in animal research.

Antihypertensive Drug Interactions

The randomized hypertension trial included patients already using up to two antihypertensive drugs alongside 3 g/day N. jatamansi. A clinical trial demonstrated that N. jatamansi can significantly decrease systolic and diastolic blood pressure in patients with essential hypertension. Given this blood pressure-lowering effect, additive hypotensive effects with antihypertensive medications are plausible and have not been fully characterized.

Pregnancy and Special Populations

No controlled human studies have evaluated the safety of N. jatamansi in pregnancy, lactation, pediatric populations, or in patients with significant hepatic or renal impairment. The scientific literature contains primarily phytochemical and animal studies of N. jatamansi's activity on the nervous system and the cardiovascular system; clinical trial data are lacking to recommend use for any indication.

Conservation-Related Adulteration Concern

Nardostachys jatamansi DC. and Selinum vaginatum (Edgew) Cl. are two endemic high-altitude Indian medicinal plants known as "Jatamansi" and "Bhootkeshi," respectively. These are used in various traditional herbal formulations and nutraceuticals. They resemble each other in their external morphological characters and characteristic odour, so their roots are often confused with each other. Given the plant's critically endangered status and commercial demand, adulteration of market preparations is a documented concern, with pharmacognostic and molecular authentication methods recommended to verify identity.

9. Overview of Evidence Quality

The scientific literature contains primarily phytochemical and animal studies of N. jatamansi's activity on the nervous system and the cardiovascular system. Clinical trial data are lacking to recommend use for any indication. The majority of pharmacological evidence derives from:

In vitro (cell-based) studies — demonstrating antioxidant, antimicrobial, cytotoxic, and enzyme-inhibiting properties.
Animal models — demonstrating antidepressant, anxiolytic, anticonvulsant, antihypertensive, hepatoprotective, and antiarrhythmic effects.
In silico / computational studies — characterizing binding affinities of key compounds (e.g., MAO-B, hERG), which provide mechanistic hypotheses but not clinical proof.
Small human trials — a limited number of underpowered, often non-blinded or non-placebo-controlled clinical studies covering insomnia, hypertension, and anxiety. These provide preliminary signals but do not constitute sufficient evidence by modern evidence-based medicine standards.

The plant's research landscape aims to consolidate knowledge on its historical significance, botanical characteristics, chemical composition, and pharmacological activities as a comprehensive resource for researchers and clinicians. Adequately powered, multi-center, randomized, double-blind, placebo-controlled trials with standardized extracts, clearly defined doses, and validated outcome measures are required before efficacy for any indication can be formally established.

References

Condiciones de Salud

Condiciones de salud que Jatamansi puede ayudar a apoyar.

Acidez EstomacalTradicional
Jatamansi (Nardostachys jatamansi) is a classical Ayurvedic herb used for anxiety, hysteria, epilepsy, and mental disorders. It modulates GABA, serotonin, and norepinephrine levels. Preclinical studies confirm anxiolytic and CNS-depressant activity. Traditional Ayurvedic texts describe it as a premier 'medhya' (mind-calming) herb. Clinical human trial data are limited.
Fibrosis QuísticaTradicional
Nardostachys jatamansi (Indian spikenard) is a classical Ayurvedic and Tibetan medicine adaptogen for stress, anxiety, and nervous exhaustion. Preclinical animal studies confirm anxiolytic and corticosterone-reducing effects via GABA modulation. Human clinical trials for stress are limited; evidence is primarily traditional and preclinical.

Sistemas Corporales

Sistemas corporales que Jatamansi puede ayudar a apoyar.

No hay sistemas corporales disponibles.